Reliq Health Technologies Stock (OTC: RQHTF)

Reliq Health Technologies (OTC:RQHTF) Stock, Quote.Headers.trade-ideas

Reliq Health Technologies Inc specializes in developing Software-as-a-Service (SaaS) solutions for remote patient monitoring, telemedicine, and care collaboration. Reliq's IUGO health technology platform is a hardware and software solution that allows complex patients to receive high-quality care in the home, improving health outcomes, enhancing the quality of life for patients and families and reducing the cost of care delivery. The firm earns through the supply of mobile device management (MDM) solutions for mobile devices and subscriptions of the iUGO CARE platform to healthcare client. The firm is based in Canada.

Cannabis

Penny Stocks

Small Cap

After-Hours Center

Markets

AGFAF

CNPOF

FFNTF

GLDFF

INLB

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

KSHB

MGCLF

MJNA

MMNFF

RQHTF

SMART CANNABIS CORP by Smart Cannabis Corp.

SCNA

SING

SPRWF

STMH

TRTC

WDDMF

ZLDAF

GAINERS:


	MedMen Enterprises Inc - Class B (Sub Voting) (OTCQX: MMNFF) shares closed up 60.85% at $ 0.27
	Singlepoint Inc (PINK: SING) shares closed up 48.28% at $0.03


Cannabis Stock Gainers And Losers From February 4, 2021

AUSAF

CNTTQ

HEXO

MRMD

TGIFF

ZBISF

CSE:NGW

GAINERS:


	Medical Marijuana Inc (PINK: MJNA) shares closed up 36.30% at $0.04
	Reliq Health Technologies Inc (PINK: RQHTF) shares closed up 33.62% at $0.58


Cannabis Stock Gainers And Losers From February 3, 2021

TSXV:RHT

Reliq Health Technologies, Inc. Announces the Launch of iUGO Well at the University of Notre Dame Australia

Reliq Health Technologies Inc. (RQHTF) Announces the Launch of iUGO Well at the University of Notre Dame Australia

RELIQ HEALTH TECHS INC by Reliq Health Technologies Inc.

Reliq Health Technologies Inc

<ul>
<li>Underscores unique position as a vertically integrated, diversified global producer of lithium chemicals with low-cost and high-quality assets</li>
<li>Details ongoing expansion programs expected to more than double total sales volumes by 2028 across multiple products and regions</li>
<li>Outlines path to Adjusted EBITDA1 of $1.3 billion by 2028 supported by strong and flexible balance sheet with peak net leverage of 2.1x1,2</li>
<li>Reaffirms significant expansion potential of one of the largest and most diverse resource bases in the industry</li>
<li>Accelerating plan to deliver $125 million of merger-related cost savings roughly two years ahead of initial target</li>
<li>Executed Memorandum of Understanding (MoU) with Toyota Tsusho in key step to unlocking further synergies</li>
</ul>
<p>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>, ASX: LTM, ", Arcadium Lithium", &amp;nbsp, or the ", Company", )))), a leading global lithium chemicals producer, today provided a number of strategic updates at its inaugural 2024 Investor Day. &nbsp;During the event, the Company reviewed its operating, commercial and growth strategies while reinforcing its commitment to sustainability leadership.&nbsp; The Company also discussed its plans for disciplined volume expansion and provided a long-term financial view.</p>


News

Guidance

Events

ALTM

Arcadium Lithium's 2024 Investor Day Highlights Company's Strategic Vision And Pathway To Significant Growth; Sees Adjusted EBITDA Of $1.3B By 2028; Accelerating Plan To Deliver $125M Of Merger-Related Cost Savings Roughly 2-Years Ahead Of Initial Target

<p>Ratings for QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for QuidelOrtho, revealing an average target of $57.25, a high estimate of $61.00, and a low estimate of $50.00. Surpassing the previous average price target of $51.00, the current average has increased by 12.25%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779707_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of QuidelOrtho among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to QuidelOrtho. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of QuidelOrtho compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of QuidelOrtho's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QDEL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on QuidelOrtho analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind QuidelOrtho</h2>
<p>QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.</p>
<h3>QuidelOrtho's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining QuidelOrtho's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-4.22%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> QuidelOrtho's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-23.19%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> QuidelOrtho's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-4.56%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> QuidelOrtho's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.21%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.87</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

QDEL

Cracking The Code: Understanding Analyst Reviews For QuidelOrtho

<p>4 analysts have expressed a variety of opinions on Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.5, a high estimate of $9.00, and a low estimate of $8.00. Witnessing a positive shift, the current average has risen by 9.68% from the previous average price target of $7.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779681_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Hain Celestial Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hain Celestial Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hain Celestial Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Hain Celestial Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Hain Celestial Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HAIN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hain Celestial Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Hain Celestial Group</h2>
<p>The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby &amp; kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas among others. It operates under two reportable segments; North America and International. The majority of its revenue is derived from the North America segment which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.</p>
<h3>Unraveling the Financial Story of Hain Celestial Group</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Hain Celestial Group's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-6.48%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Hain Celestial Group's net margin excels beyond industry benchmarks, reaching <strong>-0.7%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Hain Celestial Group's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.31%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Hain Celestial Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.14%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.89</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HAIN

Demystifying Hain Celestial Group: Insights From 4 Analyst Reviews

<p>In the latest quarter, 4 analysts provided ratings for Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.75, a high estimate of $44.00, and a low estimate of $39.00. Witnessing a positive shift, the current average has risen by 4.49% from the previous average price target of $39.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779669_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Harley-Davidson's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Robin Farley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Harley-Davidson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Harley-Davidson compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Harley-Davidson's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Harley-Davidson's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HOG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Harley-Davidson analyst ratings.</strong></a></p>
<h2>All You Need to Know About Harley-Davidson</h2>
<p>Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 38% of the heavyweight domestic market in 2023.</p>
<h3>A Deep Dive into Harley-Davidson's Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Harley-Davidson's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>11.99%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Harley-Davidson's net margin is impressive, surpassing industry averages. With a net margin of <strong>13.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.44%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Harley-Davidson's ROA excels beyond industry benchmarks, reaching <strong>1.74%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.19</strong>, Harley-Davidson faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Harley-Davidson In The Eyes Of 4 Experts

<p>During the last three months, 7 analysts shared their evaluations of Driven Brands Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRVN#NASDAQ">DRVN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Driven Brands Hldgs and provided 12-month price targets. The average target is $17.29, accompanied by a high estimate of $20.00 and a low estimate of $14.00. This current average reflects an increase of 5.88% from the previous average price target of $16.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779659_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Driven Brands Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Tristan Thomas-Martin</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Driven Brands Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Driven Brands Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Driven Brands Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Driven Brands Hldgs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DRVN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Driven Brands Hldgs analyst ratings.</strong></a></p>
<h2>Get to Know Driven Brands Hldgs Better</h2>
<p>Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes.</p>
<h3>Driven Brands Hldgs: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Driven Brands Hldgs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>0.78%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>4.93%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.26%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Driven Brands Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.46</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DRVN

Forecasting The Future: 7 Analyst Projections For Driven Brands Hldgs

<p>Ratings for Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.0, along with a high estimate of $21.00 and a low estimate of $15.00. Highlighting a 8.86% decrease, the current average has fallen from the previous average price target of $19.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779650_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Elanco Animal Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Elanco Animal Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Elanco Animal Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Elanco Animal Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Elanco Animal Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ELAN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Elanco Animal Health analyst ratings.</strong></a></p>
<h2>All You Need to Know About Elanco Animal Health</h2>
<p>Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.</p>
<h3>Elanco Animal Health's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Elanco Animal Health's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>12.02%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Elanco Animal Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-4.22%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Elanco Animal Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-0.83%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Elanco Animal Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.36%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Elanco Animal Health's debt-to-equity ratio is below the industry average at <strong>0.96</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ELAN

Demystifying Elanco Animal Health: Insights From 4 Analyst Reviews

<p>Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for MP Materials, presenting an average target of $19.12, a high estimate of $30.00, and a low estimate of $12.50. This current average represents a 5.77% decrease from the previous average price target of $20.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779624_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive MP Materials is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$12.50</td>
<td>$13.50</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$16.50</td>
<td>-</td>
</tr>
<tr>
<td>Lawson Winder</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MP Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of MP Materials compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for MP Materials's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MP Materials's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MP Materials analyst ratings.</strong></a></p>
<h2>About MP Materials</h2>
<p>MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.</p>
<h3>Unraveling the Financial Story of MP Materials</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, MP Materials faced challenges, resulting in a decline of approximately <strong>-51.18%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> MP Materials's net margin is impressive, surpassing industry averages. With a net margin of <strong>-108.95%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MP Materials's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-3.03%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> MP Materials's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-1.44%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> MP Materials's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.85</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 8 Takes On MP Materials

<p>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) ("Diamondback") announced today the launch of an underwritten public offering of 11,270,000 shares of its common stock by certain Legacy Endeavor Stockholders (the "Selling Stockholders"), subject to market and other conditions (the "Secondary Offering"). Diamondback will not receive any proceeds from the sale of the shares by the Selling Stockholders. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1,390,500 shares of common stock.<br /><br />&nbsp;</p>
<p>In addition, Diamondback has authorized the purchase from the underwriters of 2,000,000 shares of common stock offered in the Secondary Offering (the "Share Repurchase"). The Share Repurchase is part of the Diamondback's existing share repurchase program. Diamondback intends to fund the Share Repurchase from existing cash on hand. The underwriters will not receive any compensation for the shares being repurchased by Diamondback in the Share Repurchase.</p>
<p>Evercore ISI, Citigroup and J.P. Morgan are acting as joint book-running managers for the Secondary Offering.</p>


Offerings

FANG

Diamondback Energy Announces Launch Of Secondary Common Stock Offering Of 11.27M Shares Of Common Stock; Diamondback Has Authorized The Purchase From The Underwriters Of 2M Shares Of Common Stock Offered In The Secondary Offering As Part Of Its Existing Repurchase Program

<p>After a bullish session on Thursday, with both the S&amp;P 500 and the Dow Jones hitting record highs, spurred by increased risk appetite following a bold 0.5% rate cut by the Federal Reserve, traders are gearing up for a volatile <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944143/wall-street-breaks-records-chipmakers-rally-tesla-hits-2-month-high-as-fed-cut-drives-risk">end to the week.</a></p>
<p>Friday marks a notorious &#8220;Triple Witching&#8221; day, when stock index futures, stock index options and individual stock options expire simultaneously — a convergence that historically stirs market turbulence.</p>
<p>Goldman Sachs estimates than more than $4.5 trillion in notional options exposure will expire on Friday, including $605 billion in single-stock options.  </p>
<p>According to Bloomberg, using estimates from derivatives analytical firm Asym 500, the overall notional options expiring Friday reach $5.1 trillion when including options tied to ETFs.</p>
<p>&#8220;This Friday will be the largest September-options expiration on record, driven by elevated index and ETF options volumes,&#8221; wrote Goldman Sachs analyst <strong>John Marshall</strong>. </p>
<p>While the September expiration will set a new record, it&#8217;s expected to be smaller than the previous quarterly expirations of 2024.</p>
<h3 class="wp-block-heading">A Record-Breaking Expiration Day</h3>
<p>Goldman Sachs highlighted that average daily index and ETF options volumes have reached a new high this quarter. In contrast, single-stock options trading has seen a decline. </p>
<p>The sheer magnitude of options expiring Friday could trigger a wave of volatility as traders scramble to adjust their position, and the Federal Reserve&#8217;s recent rate cut might not be enough to temper the storm.</p>
<p>Could this triple witching day spoil the market rally ignited by the Fed?</p>
<h3 class="wp-block-heading">What Is &#8216;Triple Witching&#8217;? How Did Markets Previously Perform? </h3>
<p>Triple witching refers to the simultaneous expiration of three types of derivative contracts — stock index futures, stock index options and single-stock options — on the same day, occurring quarterly on the third Friday of March, June, September and December.</p>
<p>This convergence can lead to heightened market volatility as traders close, roll over or offset their expiring contracts, often resulting in unusual price movements and increased trading volumes.</p>
<p>Looking back at the last three triple witching events, the S&amp;P 500, tracked by the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has struggled during these high-stakes trading days.</p>
<ul>
<li><strong>June 21, 2024:</strong> The S&amp;P 500 dropped 0.5%.</li>
<li><strong>March 15, 2024:</strong> The index fell by 1%.</li>
<li><strong>Dec. 15, 2023:</strong> The S&amp;P 500 declined 0.6%.</li>
</ul>
<p>Tech stocks, represented by the<strong> Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), underperformed in the last two triple witching occasions, falling 0.8% in June and 1.2% in March, while surging 0.5% in December 2023. </p>
<h3 class="wp-block-heading">Goldman Sachs Recommends VIX Calls Ahead of Volatility Spike</h3>
<p>September is historically the worst month for stock market performance.</p>
<p>According to <strong>Ryan Detrick</strong>, chief market strategist at Carson Group, the last two weeks of September are the worst period for stocks during the year, as the expert showed in a post on social media platform X.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">You are here.<br /><br />The worst two weeks of the year for stocks. <a href="https://t.co/kXDg0lXKOX">pic.twitter.com/kXDg0lXKOX</a></p>
<p>&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1835859506221461664?ref_src=twsrc%5Etfw">September 17, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>The CBOE Volatility Index (VIX), often referred to as the market&#8217;s fear gauge, has dropped significantly since its spike in August.</p>
<p>The index is sitting at 17, well below its multiyear average, and Goldman Sachs sees the VIX on the rise as we enter the seasonally volatile period.</p>
<p>Goldman Sachs&#8217; economic model estimates that, given macroeconomic conditions, the VIX should be at 24.5, suggesting the current low volatility may not last much longer.</p>
<p>The investment bank issued a recommendation for investors to hedge their portfolios using VIX calls. Specifically, Goldman Sachs analysts advise buying CBOE Volatility Index (VIX) November calls at a strike price of 18.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40942814/boeing-braces-for-turbulence-as-strikes-furloughs-send-stock-sliding-bearish-signals-pre">Boeing Braces For Turbulence As Strikes, Furloughs Send Stock Sliding, Bearish Signals Prevail</a></strong></li>
</ul>
<p><em>Photo via Shutterstock. </em></p>


Analyst Color

Equities

Broad U.S. Equity ETFs

Previews

Options

Tech

ETFs

Traders Brace For Friday Volatility As Over $5 Trillion In Options Expire: Could 'Triple Witching' Spoil Fed's Rally?

<p><strong>Nike Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) shares are jumping in Thursday&#8217;s after-hours session after the company <a href="https://www.benzinga.com/pressreleases/24/09/b40947704/nike-inc-board-of-directors-announces-long-time-nike-veteran-elliott-hill-to-return-as-president-a">announced a CEO transition</a>.</p>
<p><strong>What Happened:</strong> After the market close on Thursday, Nike announced that longtime Nike veteran <strong>Elliott Hill</strong> will become president and CEO of Nike, effective Oct. 14. Hill will also become a director on the board and a member of the executive committee.</p>
<p>The board and<strong> John Donahoe</strong> made the decision that Donahoe will retire from his role as president and CEO of Nike, effective Oct. 13. The exiting CEO will remain an advisor to the company through Jan. 31, 2025, to ensure a smooth transition.</p>
<p>&#8220;Given our needs for the future, the past performance of the business, and after conducting a thoughtful succession process, the Board concluded it was clear Elliott&#8217;s global expertise, leadership style, and deep understanding of our industry and partners, paired with his passion for sport, our brands, products, consumers, athletes, and employees, make him the right person to lead Nike&#8217;s next stage of growth,&#8221; said <strong>Mark Parker</strong>, executive chairman of Nike.</p>
<p>&#8220;Personally, I have worked with Elliott for more than 30 years and I look forward to supporting him and his senior management team as they seize the opportunities ahead.&#8221;</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/news/24/09/40941277/whats-going-on-with-nike-stock">What&#8217;s Going On With Nike Stock?</a></strong></p>
<p>Throughout his career at Nike, Hill held senior leadership positions across Europe and North America before retiring in 2020. Before his retirement, he was president of the company&#8217;s Consumer and Marketplace divisions, leading operations for Nike and Jordan brands.</p>
<p>&#8220;For 32 years, I&#8217;ve had the privilege of working with the best in the industry, helping to shape our company into the magical place it is today,&#8221; Hill said. </p>
<p>&#8220;I&#8217;m eager to reconnect with the many employees and trusted partners I&#8217;ve worked with over the years, and just as excited to build new, impactful relationships that will move us ahead.&#8221;</p>
<p><strong>NKE Price Action:</strong> Nike shares closed Thursday up 0.099%. At publication time, the stock was up 10.01% at $89.09 in extended trading, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>


Sports

Management

Movers

Nike Stock Jumps 9% After The Bell, CEO Set To Retire

WIIM

BATL

Battalion Oil Corp shares are trading higher after the company announced it has amended its merger agreement with Fury Resources for the acquisition of all outstanding shares of Battalion at $7.00 per share in cash.

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Lowe's Companies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LOW, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 21 uncommon options trades for Lowe's Companies.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 42% bullish and 42%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $233,364, and 15 are calls, for a total amount of $1,029,627.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $200.0 to $280.0 for Lowe's Companies during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Lowe's Companies options trades today is 1165.5 with a total volume of 3,971.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Lowe's Companies's big money trades within a strike price range of $200.0 to $280.0 over the last 30 days.</p>
<h3>Lowe's Companies Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726778848_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.3</td>
<td>$7.25</td>
<td>$7.3</td>
<td>$280.00</td>
<td>$221.9K</td>
<td>1.5K</td>
<td style="text-align: right;">344</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$11.2</td>
<td>$11.15</td>
<td>$11.15</td>
<td>$250.00</td>
<td>$200.5K</td>
<td>2.0K</td>
<td style="text-align: right;">261</td>
</tr>
<tr>
<td>LOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$260.00</td>
<td>$76.6K</td>
<td>189</td>
<td style="text-align: right;">204</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$11.35</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$250.00</td>
<td>$73.7K</td>
<td>2.0K</td>
<td style="text-align: right;">414</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$250.00</td>
<td>$71.5K</td>
<td>3.0K</td>
<td style="text-align: right;">56</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lowe's Companies</h3>
<p>Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.</p>
<p>After a thorough review of the options trading surrounding Lowe's Companies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Lowe's Companies Standing Right Now?</h3>
<ul>
<li>With a volume of 2,187,069, the price of LOW is up 1.7% at $261.0. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Lowe's Companies</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $245.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Market Perform rating on Lowe's Companies, maintaining a target price of $230.<br />
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Hold rating on Lowe's Companies with a target price of $265.<br />
&#x2A; Consistent in their evaluation, an analyst from Gordon Haskett keeps a Hold rating on Lowe's Companies with a target price of $240.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Lowe's Companies, maintaining a target price of $255.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Lowe's Companies, which currently sits at a price target of $238. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Lowe's Companies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Check Out What Whales Are Doing With LOW

<p>Financial giants have made a conspicuous bearish move on Procter &amp; Gamble. Our analysis of options history for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $215,436, and 7 were calls, valued at $548,283.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $180.0 for Procter &amp; Gamble, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Procter &amp; Gamble's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Procter &amp; Gamble's whale trades within a strike price range from $155.0 to $180.0 in the last 30 days. </p>
<h3>Procter &amp; Gamble 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726778843_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.95</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$180.00</td>
<td>$315.9K</td>
<td>1.4K</td>
<td style="text-align: right;">38</td>
</tr>
<tr>
<td>PG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.75</td>
<td>$175.00</td>
<td>$187.5K</td>
<td>2.7K</td>
<td style="text-align: right;">600</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.95</td>
<td>$1.94</td>
<td>$1.95</td>
<td>$175.00</td>
<td>$55.6K</td>
<td>14.8K</td>
<td style="text-align: right;">611</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.79</td>
<td>$0.53</td>
<td>$0.79</td>
<td>$172.50</td>
<td>$53.6K</td>
<td>1.4K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.4</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$175.00</td>
<td>$36.8K</td>
<td>129</td>
<td style="text-align: right;">45</td>
</tr>
</tbody>
</table>
</p>
<h3>About Procter &amp; Gamble</h3>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.</p>
<p>After a thorough review of the options trading surrounding Procter &amp; Gamble, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Procter &amp; Gamble Standing Right Now?</h3>
<ul>
<li>With a trading volume of 8,632,563, the price of PG is down by -1.37%, reaching $171.54.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 27 days from now.</li>
</ul>
<h3>Expert Opinions on Procter &amp; Gamble</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $188.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Procter &amp; Gamble, targeting a price of $186.<br />
&#x2A; In a positive move, an analyst from DZ Bank has upgraded their rating to Buy and adjusted the price target to $190. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Procter &amp; Gamble options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Procter & Gamble

<p>Battalion Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BATL#NYSE">BATL</a>) ("Battalion" or the "Company") announced today that it has entered into an amendment to the previously disclosed Agreement and Plan of Merger (as amended, the&nbsp;"Merger Agreement") with Fury Resources, Inc. ("Buyer" or "Parent"), pursuant to which Parent has agreed to acquire all of the outstanding shares of Common Stock of the Company (the&nbsp;"Common Stock") for $7.00 per share in cash, without interest (the "Merger Consideration"). The holders of all of the outstanding shares of the Preferred Stock of the Company, Luminus Management, LLC ("Luminus"), Gen IV Investment Opportunities, LLC, and funds and accounts managed by Oaktree Capital Management, L.P. ("Oaktree"), or their respective affiliates&nbsp; (collectively, the "Rollover Stockholders"), have agreed to contribute to Buyer all of their shares of Preferred Stock of the Company in exchange for new preferred shares of Buyer at a valuation based on the redemption value of such Company Preferred Stock.</p>
<p>The transaction is expected to close in the fourth quarter of 2024, subject to various closing conditions as set forth in the Merger Agreement, including the approval of Battalion's stockholders.</p>
<p>Parent has confirmed to the Company that it has received the following capital commitments to complete the transactions contemplated by the Merger Agreement:</p>
<ul>
<li>$200&nbsp;million in debt commitments from Fortress Credit Corp. and AI Partners Asset Management Co., Ltd;</li>
<li>$188&nbsp;million in total Preferred Stock commitments from a combination of the Rollover Stockholders listed above ($173 million) and AI Partners Asset Management Co., Ltd. ($15&nbsp;million);</li>
<li>$160&nbsp;million in equity commitments to acquire new shares of common stock of Parent.<br /><br /><br /><br />&nbsp;</li>
</ul>
<p>Post-transaction, net of acquisition consideration and fees, Parent is expected to have approximately $100 million in cash on the balance sheet.</p>
<p>As previously disclosed, in connection with the transactions contemplated by the Merger Agreement, Luminus and Oaktree, who collectively own 61.61% of the Common Stock of the Company, had entered into a Voting Agreement with Buyer pursuant to which they have agreed, among other things, to vote 6,254,652 of their shares of Common Stock, which in the aggregate represents 38% of the total voting power of the shares of capital stock of the Company, in favor of adopting the Merger Agreement.</p>
<p>For Battalion, Houlihan Lokey Capital, Inc. acted as financial advisor and Mayer Brown LLP is acting as legal counsel. Jefferies LLC acted as financial advisor and K&amp;L Gates LLP is acting as legal counsel to Buyer.</p>


Battalion Oil Corporation Announces Amendment To Merger Agreement With Fury Resources, Inc. For $7.00 Per Share In Cash

Insider Trades

Trading Ideas

ADBE

Adobe CFO Daniel Durn Reports Open Market Sale Of 4,500 Shares at $515.23/Share And 2,000 Shares at $515.90/Share On September 17

<p>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) (&quot;Chewy&quot;), a trusted destination for pet parents and partners everywhere, announced today the commencement of an underwritten offering of $500 million of shares of its Class A common stock, par value $0.01 per share, by Buddy Chester Sub LLC (the &quot;Selling Stockholder&quot;), which is an entity affiliated with funds advised by BC Partners Advisors LP (&quot;BC Partners&quot;), Chewy&#39;s largest shareholder (the &quot;Offering&quot;). The Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of Class A common stock. Chewy will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholder. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.</p>
<p>In addition, Chewy has agreed to purchase from the Selling Stockholder $300 million of Chewy&#39;s Class A common stock at a price per share equal to the per share purchase price to be paid by the underwriters in the Offering specified above (the &quot;Concurrent Repurchase&quot;). The Concurrent Repurchase was approved by a special committee of Chewy&#39;s Board of Directors, consisting solely of independent and disinterested directors not affiliated with BC Partners. The repurchased shares will be cancelled and retired upon completion of the Concurrent Repurchase. The Concurrent Repurchase is being executed separately from the Company&#39;s existing $500 million share repurchase program authorized on May 24, 2024, which will be unaffected by this transaction. The Concurrent Repurchase is expected to be consummated concurrently with the Offering. The Offering is not conditioned upon the closing of the Concurrent Repurchase, but the Concurrent Repurchase is conditioned upon the closing of the Offering.</p>


CHWY

Chewy Announces A $500M Underwritten Offering Of Shares By Its Largest Shareholder, Buddy Chester Sub LLC; Chewy Will Concurrently Repurchase $300M Of Its Stock From The Selling Stockholder At The Offering Price, Separate From Its Existing Share Repurchase Program

Chewy shares are trading lower after the company announced the public offering of shares by a selling stockholder and a concurrent share repurchase.

Biotech

General

ANGO

AngioDynamics Initiates RECOVER-AV Clinical Trial Of AlphaVac F18⁸⁵ System In Pulmonary Embolism And Long-Term Functional Outcomes

<p><strong>VinFast Auto Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) shares traded higher Thursday after the Federal Reserve cut interest rates by 50 basis points (bps) on Wednesday. <strong>The company will report its second-quarter results before Friday's opening bell and host a conference call at 8 a.m. ET to discuss the results.</strong></p>
<h1 class="wp-block-heading"><strong>Here's A <a href="https://www.benzinga.com/markets/equities/24/09/40866380/tesla-china-shines-lucid-gives-peek-into-model-y-rival-ford-eyes-electric-restart-in-india-and-m">Look At What To Know&nbsp;</a></strong></h1>
<p><strong>What Happened:</strong> VinFast Auto shares closed higher Thursday amid a broad <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944143/wall-street-breaks-records-chipmakers-rally-tesla-hits-2-month-high-as-fed-cut-drives-risk">market rally </a>as investors digested the Fed's larger-than-anticipated interest rate cut which marked the first in more than four years.</p>
<p>The rate cut brings the federal funds rate down to a range of 4.75% to 5% and will reduce the cost of borrowing for companies and consumers.&nbsp;</p>
<p>According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report quarterly losses of 21 cents per share and $460.089 million in revenue.&nbsp;</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today"><strong>What Happened With SoFi Stock Today?</strong></a></p>
<p><strong>What Else:</strong> Last week, the National Highway Traffic Safety Administration initiated a probe into VinFast's EVs based on complaints from vehicle owners. The probe covered around 3,118 vehicles manufactured in 2023 and 2024, with owners alleging that the vehicles had problems with the &#8220;Lane Keep Assist&#8221; system. </p>
<p>Owners claimed the EVs had difficulty detecting lanes on the roadway and provided improper steering inputs.&nbsp;</p>
<h1 class="wp-block-heading"><strong>Will VFS Stock Go Up?</strong></h1>
<p>When trying to assess whether or not VinFast Auto will trade higher from current levels, it's a good idea to take a look at analyst forecasts.</p>
<p>Wall Street analysts have an average 12-month price target of $8 on VinFast Auto. Of all the analysts covering VinFast Auto, six have positive ratings, no one has a neutral rating and no one has a negative rating.</p>
<p>In the last month, two analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/VFS/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering VinFast Auto have performed in recent history.</p>
<p>Stocks don't move in a straight line. The average stock market return is approximately 10% per year. VinFast Auto is 43.83% down year-to-date. The average analyst price target suggests the stock could have further upside ahead.</p>
<p>For a broad overview of everything you need to know about VinFast Auto, visit <a href="https://www.benzinga.com/quote/VFS">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.</p>
<p><strong>VFS Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, VinFast Auto shares ended Thursday's session 2.06% higher at $3.96.&nbsp;</p>
<p><strong>Read Also:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40923038/whats-going-on-with-carnival-stock"><strong>What&#8217;s Going On With Carnival Stock?</strong></a></li>
</ul>
<p><em>Photo: Shutterstock </em></p>


What's Going On With VinFast Auto Stock?

<p>Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported quarterly earnings of $3.90 per share which beat the analyst consensus estimate of $3.63 by 7.44 percent. The company reported quarterly sales of $9.416 billion which beat the analyst consensus estimate of $9.164 billion by 2.76 percent. This is a 7.86 percent increase over sales of $8.730 billion the same period last year.</p>


Earnings

Lennar Q3 2024 Adj. EPS $3.90 Beats $3.63 Estimate, Sales $9.416B Beat $9.164B Estimate

Reliq Health Technologies reports new contract with U.S. physician network

Reliq Health Technologies Inc (RQHTF) stock is lower by -23.08% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives RQHTF stock a score of  13 out of a possible 100. That rank is mainly influenced by a short-term technical score of 13. RQHTF's rank also includes a long-term technical score of 25.

Is Reliq Health Technologies Inc (RQHTF) Stock a Bad Value?

Overall market sentiment has been down on Reliq Health Technologies Inc (RQHTF)  stock lately. RQHTF receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. Reliq Health Technologies Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RQHTF!See Full

What is the Market's View on Reliq Health Technologies Inc (RQHTF) Stock's Price and Volume Trends Friday?

Reliq Health Technologies Inc (RQHTF) is around the bottom of the Healthcare sector according to InvestorsObserver.RQHTF received an overall rating of 9, which means that it scores higher than 9% of stocks. Additionally, Reliq Health Technologies Inc scored a 3 in the Healthcare sector, ranking it higher than 3% of stocks

Will Reliq Health Technologies Inc (RQHTF) Underperform the Rest of the Stocks in the Healthcare Sector?

Reliq Health Technologies Inc (RQHTF) stock is down -44.74% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives RQHTF stock a score of  0 out of a possible 100. That rank is  influenced by a short-term technical score of 0. RQHTF's rank also includes a long-term technical score of 0.  RQHTF has a

Is Reliq Health Technologies Inc (RQHTF) Stock a Smart Value?

Reliq Health announces new contracts with 10 physician practices in FL, TX and NV

Reliq Health Technologies announces expansion of contract with large US health plan

Reliq Health Technologies Inc (RQHTF) is around the bottom of the Healthcare sector according to InvestorsObserver.RQHTF received an overall rating of 8, which means that it scores higher than 8% of stocks. Additionally, Reliq Health Technologies Inc scored a 3 in the Healthcare sector, ranking it higher than 3% of stocks

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Reliq Health Technologies

Reliq Health Technologies (RQHTF) Forecast

Reliq Health Technologies (OTC:RQHTF) Stock, Quote.Headers.trade-ideas